DRDO issues directions for usage of anti-Covid drug 2-DG on patients


Defence Minister Rajnath Singh and Union Health Minister Harsh Vardhan released the first batch of Anti-Covid drug 2DG developed by DRDO, on 17 May 2021 | Twitter/@drharshvardhan


Text Size:

New Delhi: The DRDO on Tuesday issued directions on the usage of its 2-DG drug on COVID-19 patients, stating that caution should be exercised while prescribing this medicine to people who have comorbidities such as uncontrolled diabetes, severe cardiac problem and acute respiratory distress syndrome.

The Drugs Controller General of India (DCGI) approved the 2-deoxy-D-glucose (2-DG) drug for emergency use as an adjunct therapy in moderate to severe coronavirus patients in early May.

The first batch of this oral drug, developed by the Defence Research and Development Organisation (DRDO), was released on May 17 by Defence Minister Rajnath Singh and Health Minister Harsh Vardhan.

On Tuesday, the DRDO on Twitter issued “directions for usage of this drug for COVID-19 patients as per DCGI approval”.

“Ideally, 2DG should be prescribed as early as possible by doctors for moderate to severe COVID-19 patients for maximum duration up to 10 days,” it mentioned.

Uncontrolled diabetes, severe cardiac problem, acute respiratory distress syndrome, severe hepatic and renal impairment patients have not been studied yet with 2DG, hence caution should be exercised, it noted.

“2DG should not be given to pregnant and lactating women and patients below 18 years,” it stated.

Patients or their attendants are advised to request their hospital to contact Dr Reddy’s Laboratories (DRL) for medicine supply.

The anti-COVID-19 therapeutic application of 2-DG drug has been developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a leading laboratory of DRDO, in collaboration with DRL.

The DRDO said the drug is approved for emergency use as adjunct therapy to the standard treatment of COVID-19 patients in the hospital settings.

The defence ministry on May 8 said that the clinical trials of 2-DG showed that it helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence.

The approval of the drug has come at a time India has been grappling with a record-breaking wave of coronavirus pandemic that has stretched the country’s healthcare infrastructure to its limit.

The drug comes in powder form in sachet and is taken orally by dissolving it in water.

In efficacy trends, the defence ministry said, patients treated with 2-DG showed faster symptomatic cure than the standard of care on various endpoints.-PTI


Also read: DRDO’s first batch of anti-Covid drug 2-DG released


 

Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

India needs free, fair, non-hyphenated and questioning journalism even more as it faces multiple crises.

But the news media is in a crisis of its own. There have been brutal layoffs and pay-cuts. The best of journalism is shrinking, yielding to crude prime-time spectacle.

ThePrint has the finest young reporters, columnists and editors working for it. Sustaining journalism of this quality needs smart and thinking people like you to pay for it. Whether you live in India or overseas, you can do it here.

Support Our Journalism